Dulaglutide: a review in type 2 diabetes
Compliance with Ethical Standards
Funding The preparation of this review was not supported by any external funding.
Conflicts of interest Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found here
dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist that is
approved in numerous countries as an adjunct to diet and exercise for the
treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous
dulaglutide, as monotherapy or add-on therapy to other antihyperglycaemic drugs
(including oral antihyperglycaemic drugs and insulin), was an effective and
generally well tolerated treatment in adults with inadequately controlled T2D, including
in high-risk patients [e.g. obese and elderly patients, those with stage 3 or 4
chronic kidney disease (CKD) and/or cardiovascular (CV) disease]. In the REWIND
CV outcomes trial in patients with T2D with or without CV disease, dulaglutide
was associated with a significant reduction in the risk of a major adverse
cardiac event (MACE; primary composite outcome comprising CV death, nonfatal
myocardial infarction or nonfatal stroke) at a median of 5.4 years’ follow-up. Given
its durable glycaemic efficacy, beneficial effects on bodyweight and MACE
outcomes, low inherent risk of hypoglycaemia and convenient once-weekly
regimen, dulaglutide remains an important option in the management of T2D.
© Springer Nature Switzerland AG 2020